Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endostar + doxorubicin + ifosfamide
- Development stage
- Unknown
- Lead developer
- Jiangsu Simsheng Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
Endostar + doxorubicin + ifosfamide is a combination therapeutic regimen being investigated for the treatment of soft tissue sarcoma. The regimen consists of Endostar (recombinant human endostatin), an anti-angiogenic biologic agent, and the AI chemotherapy combination, which includes the cytotoxic small molecules doxorubicin (an anthracycline) and ifosfamide (an alkylating agent). Endostar works by inhibiting tumor angiogenesis, thereby depriving the tumor of necessary blood supply, while doxorubicin and ifosfamide target the DNA of rapidly dividing cancer cells to induce cell death. This specific combination is currently being evaluated in a Phase II clinical trial led by Yong Chen at Fudan University Shanghai Cancer Center as an adjuvant treatment following radical resection of recurrent stage IIB/III soft tissue sarcoma.
- Brand names
- EndostarAdriamycin
- Other names
- Endostar + AI regimenEndostar + AI chemotherapyChemotherapy AI-Yong Chen-soft tissue sarcoma
02
Targets
DNATOP2A (DNA topoisomerase II)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on Endostar + doxorubicin + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endostar + doxorubicin + ifosfamide.